Results 111 to 120 of about 993 (163)

Molecular Mechanisms, Diagnosis, and Therapeutic Strategies of Antifungal Resistance in Filamentous Fungi

Journal of Fungi
Antifungal resistance in filamentous fungi has emerged as a major threat to global public health, posing a serious challenge particularly to immunocompromised populations. This review provides a systematic overview of the molecular mechanisms, diagnostic
Yajing Yin, Yueru Zhao, Meng Zhao, Lipeng Zhang, Ruijie Li, Lei Liu   +5 more
doaj   +1 more source

P-1958. Efficacy and Safety of Rezafungin, A Long-Acting Echinocandin [PDF]

Open Forum Infect Dis
Abstract Background Rezafungin (RZF), a novel long-acting intravenous echinocandin, was approved by the FDA in March 2023 for adult patients (pts) with candidemia and invasive candidiasis and safety data for up to 4 weekly doses.
Hengel, Richard L, Metzger, Brian S, Young, Erika M, Stock, Kent J, John, Joseph F, Couch, Kimberly A, Weeks, Christina J, Van Anglen, Lucinda J   +7 more
europepmc   +2 more sources

Candidemia: An Update on Epidemiology, Risk Factors, Diagnosis, Susceptibility, and Treatment

Pathogens
Candidemia is a highly prevalent invasive fungal infection caused primarily by C. albicans, C. parapsilosis, C. glabrata (currently Nakaseomyces glabratus), C. tropicalis, and C. krusei (currently Pichia kudriavzevii). Risk factors for the development of
Juan Pablo Cabrera-Guerrero, Eduardo García-Salazar, Graciela Hernandez Silva, Alberto Chinney Herrera, Erick Martínez-Herrera, Rodolfo Pinto-Almazán, María Guadalupe Frías-De-León, Carlos Alberto Castro-Fuentes   +7 more
doaj   +1 more source

The use of Rezafungin as an accelerator in the treatment of invasive candidiasis compared to caspofungin

The main scope of this research is to analyze the innovative development of Rezafungin by evaluating its mechanism of antifungal action in comparison with caspofungin in patients undergoing treatment for invasive ...
Sarah Letícia Alves da Cruz, Karolyna de Oliveira Ramos, Maria Beatriz de Alencar Palma, João Vitor Souza de Almeida, Letícia de Carvalho Costa, Marina Barboza Marques Ramos, Maria Eduarda Brito Dantas, Ana Carolina de Siqueira Guedes, Ana Sofia Remígio Carvalheira   +8 more
core   +1 more source

A US Hospital-Perspective Decision-Analytic Model of Once-Weekly Rezafungin Versus Daily Echinocandin Therapy in Hospitalized Adults With Candidemia or Invasive Candidiasis: Potential Cost Savings From Earlier Discharge. [PDF]

Open Forum Infect Dis
Lodise TP, Patel N.
europepmc   +1 more source

Efficacité et tolérance en vie réelle de la rezafungin dans le traitement des infections fongiques invasives en France

International audienceIntroductionLa rezafungin est une échinocandine de nouvelle génération avec une demi-vie prolongée permettant une administration hebdomadaire.
Dannoui, E., Botterel, F., Chantelot, L., Millon, L., Lanternier, F., Bes, H., Issa, N., Godet, C., Morio, F., Andrejak, C., Desaubeaux, G., Parize, P.   +11 more
core   +1 more source

Rezafungin and catheter-related candidemia: a new player in a high-stakes game. [PDF]

Infez Med
Venturini S, Reffo I, Zanus-Fortes A, Del Fabro G, Callegari A, Giovagnorio F, Negri C, Casarotto M, Basaglia G, Zanusso C, Basso B.   +10 more
europepmc   +1 more source

<i>Candidozyma auris</i> susceptibility from Michigan hospitals to manogepix, rezafungin and nine other antifungal agents. [PDF]

JAC Antimicrob Resist
Klamer KS, Bhargava A, Johnson L, Sharma M, Saravolatz LD.   +4 more
europepmc   +1 more source

Rezafungin for the treatment of invasive candidiasis secondary to esophagogastric anastomotic leak: clinical success in a complex situation. [PDF]

Rev Esp Quimioter
Estévez A, Lalinde D, Ramos R, Piñeiro P, Muñoz P.   +4 more
europepmc   +1 more source

Bad to the bone: <i>Candida (Candidozyma) auris</i> vertebral osteomyelitis treated with combination antifungal therapy followed by a novel long-acting echinocandin. [PDF]

ASM Case Rep
Jenkins LB, Christian RL, Karaman BA, Ghannoum MA, Dousa KM.   +4 more
europepmc   +1 more source